Published in Oncotarget on June 29, 2017
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Parkinson's disease. Hum Mol Genet (2007) 3.84
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem (2001) 2.18
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods (1997) 2.04
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience (2001) 1.96
Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord (2006) 1.49
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol (1985) 1.30
MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci (1988) 1.16
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014) 1.05
Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol (2011) 1.00
Glutamate-stimulated ATP release from spinal cord astrocytes is potentiated by substance P. J Neurochem (2006) 0.98
The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol (2014) 0.92
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp Neurol (2015) 0.90
Parkinson's disease: Autoimmunity and neuroinflammation. Autoimmun Rev (2016) 0.90
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Intern Med (2013) 0.88
Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain (2014) 0.86
Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther (2007) 0.86
Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci Lett (2014) 0.82
Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+. Neurosci Lett (1986) 0.81
Time-Dependent Protection of CB2 Receptor Agonist in Stroke. PLoS One (2015) 0.78
Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation. Oncotarget (2016) 0.78
Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats. Exp Neurol (2017) 0.78
Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways. Toxicol Appl Pharmacol (2017) 0.78